全球乾癬治療市場，依藥物類別（皮質類固醇、TNF抑制劑、白血球介素、其他）、類型（斑塊狀乾癬、乾癬性關節炎、其他）、給藥途徑（口服、注射、外用）、應用（外用治療藥物、全身治療藥物、合併用藥）、最終使用者（醫院藥局、診所、零售藥局、線上銷售）、國家（美國、加拿大、墨西哥、秘魯、巴西、阿根廷、南美洲其他國家、德國、義大利、英國、法國、西班牙、荷蘭、比利時、瑞士、土耳其、俄羅斯、匈牙利、立陶宛、奧地利、愛爾蘭、挪威、波蘭、歐洲其他國家/地區、日本、中國、印度、韓國、澳洲、新加坡、馬來西亞、泰國、印尼、菲律賓、越南、亞太其他國家/地區、南非、沙烏地阿拉伯、阿聯酋、科威特、以色列、埃及、中東和非洲其他國家）劃分，
全球銀屑病治療市場分析與洞察
預計2022年至2029年預測期內，乾癬治療市場將以7.85%的複合年增長率成長。 Data Bridge Market Research發布的乾癬治療市場報告分析並深入探討了預測期內各種影響因素及其對市場成長的影響。全球慢性病盛行率的上升正在推動銀屑病治療市場的成長。
銀屑病是一種慢性發炎性皮膚病，通常與全身性疾病有關。這種遺傳性疾病可能先天存在，也可能不存在，但也可能由遺傳和環境因素誘發。
全球銀屑病盛行率的上升是推動銀屑病治療市場成長的主要因素之一。製造商之間合作的增加以及人們對治療認識的提高加速了市場成長。新興經濟體疾病負擔的加重和對銀屑病藥物需求的增加，以及政府相關措施的增加，進一步影響市場。此外，技術進步、人口成長、治療研發投入的增加以及醫療保健支出的增加也對銀屑病治療市場產生正面影響。此外，銀屑病研究的增加和在研藥物的增多，為2022年至2029年預測期內的市場參與者提供了更多盈利機會。
另一方面，藥物研發和大多數治療的高昂成本預計將阻礙市場成長。藥物審批的延遲預計將在2022-2029年的預測期內對銀屑病治療市場構成挑戰。
這份銀屑病治療市場報告詳細介紹了近期新進展、貿易法規、進出口分析、生產分析、價值鏈優化、市場份額、國內外市場參與者的影響、新興收入來源的機遇分析、市場法規變化、戰略市場增長分析、市場規模、各細分市場增長、應用領域及主導地位、產品審批、產品發布、地域擴張以及市場技術創新。如需了解更多關於銀屑病治療市場的信息，請聯繫Data Bridge Market Research索取分析師簡報，我們的團隊將幫助您做出明智的市場決策，實現市場成長。
全球銀屑病治療市場範圍和市場規模
銀屑病治療市場按藥物類別、類型、給藥途徑、應用和最終用戶進行細分。各細分市場的成長情況有助於您分析潛在的成長點和市場策略，確定您的核心應用領域以及目標市場的差異。
- 根據藥物類別，乾癬治療市場分為皮質類固醇、TNF抑制劑、白血球介素和其他藥物。
- 根據類型，銀屑病治療市場分為斑塊狀乾癬、銀屑病關節炎和其他類型。
- 根據給藥途徑，乾癬治療市場分為口服、注射和外用三種類型。
- 根據應用方式，乾癬治療市場分為局部用藥、全身用藥和合併用藥。
- 根據分銷管道，銀屑病治療市場分為醫院藥房、診所、零售藥房和線上銷售。
銀屑病治療市場國家層級分析
對銀屑病治療市場進行分析，並按國家、藥物類別、治療方法、最終用戶和分銷渠道提供市場規模信息，如上所述。
全球銀屑病治療市場報告涵蓋的國家包括：北美洲的美國、加拿大和墨西哥；南美洲的秘魯、巴西、阿根廷和南美洲其他國家；歐洲的德國、義大利、英國、法國、西班牙、荷蘭、比利時、瑞士、土耳其、俄羅斯、匈牙利、立陶宛、奧地利、愛爾蘭、挪威、波蘭和歐洲其他國家；亞太地區的日本、中國、印度、韓國、澳洲、新加坡、馬來西亞、泰國、印尼、菲律賓、越南和亞太地區的其他國家；以及中東和非洲地區的南非、沙烏地阿拉伯、阿聯酋、科威特、以色列、埃及和中東和非洲其他國家。
由於北美地區擁有發達的醫療保健基礎設施，因此在銀屑病治療市場佔據主導地位。亞太地區人口眾多，預計在2022年至2029年的預測期內，該地區將實現高速成長。
報告的國別部分還提供了影響各個市場的因素以及國內市場監管變化，這些因素和變化會影響市場的當前和未來趨勢。新銷售額、替換銷售額、國家人口統計、疾病流行病學和進出口關稅等數據點是預測各國市場前景的主要指標。此外，在對各國數據進行預測分析時，也會考慮全球品牌的市場佔有率和可用性，以及它們因本地品牌競爭激烈或稀缺而面臨的挑戰，以及銷售管道的影響。
患者流行病學分析
銀屑病治療市場報告也提供詳細的市場分析，涵蓋患者分析、預後和治療方案。報告中提供的數據變數包括盛行率、發病率、死亡率和依從率等。報告分析了流行病學對市場成長的直接或間接影響，旨在建立更穩健的隊列多元統計模型，從而預測市場在增長期內的發展趨勢。
競爭格局及乾癬治療市場佔有率分析
銀屑病治療市場競爭格局分析報告按競爭對手提供了詳細信息，包括公司概況、財務狀況、收入、市場潛力、研發投入、新市場拓展計劃、全球佈局、生產基地及設施、產能、公司優勢與劣勢、產品發布、產品線寬度與廣度以及應用領域優勢。以上數據僅與各公司專注於的銀屑病治療市場相關。
銀屑病治療市場報告的主要參與者包括禮來公司、輝瑞公司、強生全球服務有限公司、新基公司、武田製藥有限公司、諾華國際股份公司、安進公司、百健公司、艾伯維公司、阿斯特捷利康、勃林格殷格翰國際有限公司、百健、強生服務公司、默克公司、太陽製藥工業有限公司、施泰福實驗室、優時比公司、利奧製藥、西普拉公司、羅文生物製藥公司、格蘭馬克製藥公司和Win-Medicare私人有限公司等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PSORIASIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL PSORIASIS TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PSORIASIS TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH DERMATOLOGIST
6.8 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL PSORIASIS TREATMENT MARKET, BY DISEASE TYPE
11.1 OVERVIEW
11.2 PLAQUE PSORIASIS, BY TREATMENT
11.2.1 MEDICATION
11.2.1.1. CORTICOSTEROIDS
11.2.1.1.1. HYDROCORTISONE, BY BRAND
11.2.1.1.1.1 HYDROCORT
11.2.1.1.1.1.1. MARKET VALUE (USD MN)
A. MARKET VOLUME (IU)
B. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.2 ALPHOSYL
11.2.1.1.1.2.1. MARKET VALUE (USD MN)
11.2.1.1.1.2.2. MARKET VOLUME (IU)
11.2.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.3 AQUACORT
11.2.1.1.1.3.1. MARKET VALUE (USD MN)
11.2.1.1.1.3.2. MARKET VOLUME (IU)
11.2.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.4 OTHERS
11.2.1.1.2. TRIAMCINOLONE, BY BRAND
11.2.1.1.2.1 KENALOG IV
11.2.1.1.2.1.1. MARKET VALUE (USD MN)
11.2.1.1.2.1.2. MARKET VOLUME (IU)
11.2.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.2.2 ARISTOSPAN
11.2.1.1.2.2.1. MARKET VALUE (USD MN)
11.2.1.1.2.2.2. MARKET VOLUME (IU)
11.2.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.2.3 TRIVARIS
11.2.1.1.2.3.1. MARKET VALUE (USD MN)
11.2.1.1.2.3.2. MARKET VOLUME (IU)
11.2.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.2.4 OTHERS
11.2.1.1.3. CLOBETASOL, BY BRAND
11.2.1.1.3.1 TEMOVATE
11.2.1.1.3.1.1. MARKET VALUE (USD MN)
11.2.1.1.3.1.2. MARKET VOLUME (IU)
11.2.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.3.2 CLOBEX
11.2.1.1.3.2.1. MARKET VALUE (USD MN)
11.2.1.1.3.2.2. MARKET VOLUME (IU)
11.2.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.3.3 OLUX
11.2.1.1.3.3.1. MARKET VALUE (USD MN)
11.2.1.1.3.3.2. MARKET VOLUME (IU)
11.2.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.3.4 OTHERS
11.2.1.2. CALCINEURIN INHIBITORS
11.2.1.2.1. TACROLIMUS, BY BRAND
11.2.1.2.1.1 PROGRAF
11.2.1.2.1.1.1. MARKET VALUE (USD MN)
11.2.1.2.1.1.2. MARKET VOLUME (IU)
11.2.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.1.2 ENVARSUS XR
11.2.1.2.1.2.1. MARKET VALUE (USD MN)
11.2.1.2.1.2.2. MARKET VOLUME (IU)
11.2.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.1.3 ASTAGRAF XL
11.2.1.2.1.3.1. MARKET VALUE (USD MN)
11.2.1.2.1.3.2. MARKET VOLUME (IU)
11.2.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.1.4 OTHERS
11.2.1.2.2. PIMECROLIMUS (ELIDEL)
11.2.1.2.2.1.1. MARKET VALUE (USD MN)
11.2.1.2.2.1.2. MARKET VOLUME (IU)
11.2.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.3. IMMUNOSUPPRESSANT
11.2.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.2.1.3.1.1 SANDMMUNE
11.2.1.3.1.1.1. MARKET VALUE (USD MN)
11.2.1.3.1.1.2. MARKET VOLUME (IU)
11.2.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.1.2 NEORAL
11.2.1.3.1.2.1. MARKET VALUE (USD MN)
11.2.1.3.1.2.2. MARKET VOLUME (IU)
11.2.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.1.3 RESTASIS
11.2.1.3.1.3.1. MARKET VALUE (USD MN)
11.2.1.3.1.3.2. MARKET VOLUME (IU)
11.2.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.1.4 OTHERS
11.2.1.3.2. METHOTREXATE, BY BRAND NAME
11.2.1.3.2.1 TREXALL
11.2.1.3.2.1.1. MARKET VALUE (USD MN)
11.2.1.3.2.1.2. MARKET VOLUME (IU)
11.2.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.2.2 OTREXUP
11.2.1.3.2.2.1. MARKET VALUE (USD MN)
11.2.1.3.2.2.2. MARKET VOLUME (IU)
11.2.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.2.3 RASUVO
11.2.1.3.2.3.1. MARKET VALUE (USD MN)
11.2.1.3.2.3.2. MARKET VOLUME (IU)
11.2.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.2.4 OTHERS
11.2.1.3.3. BIOLOGIC DRUGS
11.2.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.2.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.2.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.2.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.2.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.1.6. OTHERS
11.2.1.3.3.2 INTERLEUKIN
11.2.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
11.2.1.3.3.2.2. AVERAGE SELLING PRICE (USD SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.2.4. OTHERS
11.2.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.4. OTHERS
11.2.2 TOPICAL THERAPY
11.2.2.1. VITAMIN D
11.2.2.1.1. CALCIPOTRIENE,BY BRAND
11.2.2.1.1.1 DOVONEX
11.2.2.1.1.1.1. MARKET VALUE (USD MN)
11.2.2.1.1.1.2. MARKET VOLUME (IU)
11.2.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.2.1.1.2 SORILUX
11.2.2.1.1.2.1. MARKET VALUE (USD MN)
11.2.2.1.1.2.2. MARKET VOLUME (IU)
11.2.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.2.1.1.3 OTHERS
11.2.2.1.2. CALCITRIOL (VECTICAL)
11.2.2.1.2.1 MARKET VALUE (USD MN)
11.2.2.1.2.2 MARKET VOLUME (IU)
11.2.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.2.2.2.1. TAZORAC
11.2.2.2.1.1 MARKET VALUE (USD MN)
11.2.2.2.1.2 MARKET VOLUME (IU)
11.2.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.2. AVAGE
11.2.2.2.2.1 MARKET VALUE (USD MN)
11.2.2.2.2.2 MARKET VOLUME (IU)
11.2.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.3. OTHERS
11.2.2.3. ANTHRALIN
11.2.2.3.1. MARKET VALUE (USD MN)
11.2.2.3.2. MARKET VOLUME (IU)
11.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.2.4. SALICYLIC ACID
11.2.2.4.1. MARKET VALUE (USD MN)
11.2.2.4.2. MARKET VOLUME (IU)
11.2.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.2.5. COAL TAR
11.2.2.5.1. MARKET VALUE (USD MN)
11.2.2.5.2. MARKET VOLUME (IU)
11.2.2.5.3. AVERAGE SELLING PRICE (USD)
11.2.2.6. OTHERS
11.2.3 LIGHT THERAPY
11.2.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.2.3.2. UV B
11.2.3.2.1. BROAD BAND
11.2.3.2.2. NARROW BAND
11.2.3.3. EXCIMER LASER
11.2.4 SYMPTOMATIC MEDICINE
11.2.4.1. ALOE EXTRACT CREAM
11.2.4.1.1. MARKET VALUE (USD MN)
11.2.4.1.2. MARKET VOLUME (IU)
11.2.4.1.3. AVERAGE SELLING PRICE (USD)
11.2.4.2. FISH OIL SUPPLEMENTS
11.2.4.2.1. MARKET VALUE (USD MN)
11.2.4.2.2. MARKET VOLUME (IU)
11.2.4.2.3. AVERAGE SELLING PRICE (USD)
11.2.4.3. OREGON GRAPE
11.2.4.3.1. MARKET VALUE (USD MN)
11.2.4.3.2. MARKET VOLUME (IU)
11.2.4.3.3. AVERAGE SELLING PRICE (USD)
11.3 GUTTATE PSORIASIS
11.3.1 MEDICATION
11.3.1.1. CORTICOSTEROIDS
11.3.1.1.1. HYDROCORTISONE, BY BRAND
11.3.1.1.1.1 HYDROCORT
11.3.1.1.1.1.1. MARKET VALUE (USD MN)
11.3.1.1.1.1.2. MARKET VOLUME (IU)
11.3.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.1.2 ALPHOSYL
11.3.1.1.1.2.1. MARKET VALUE (USD MN)
11.3.1.1.1.2.2. MARKET VOLUME (IU)
11.3.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.1.3 AQUACORT
11.3.1.1.1.3.1. MARKET VALUE (USD MN)
11.3.1.1.1.3.2. MARKET VOLUME (IU)
11.3.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.1.4 OTHERS
11.3.1.1.2. TRIAMCINOLONE, BY BRAND
11.3.1.1.2.1 KENALOG IV
11.3.1.1.2.1.1. MARKET VALUE (USD MN)
11.3.1.1.2.1.2. MARKET VOLUME (IU)
11.3.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.2.2 ARISTOSPAN
11.3.1.1.2.2.1. MARKET VALUE (USD MN)
11.3.1.1.2.2.2. MARKET VOLUME (IU)
11.3.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.2.3 TRIVARIS
11.3.1.1.2.3.1. MARKET VALUE (USD MN)
11.3.1.1.2.3.2. MARKET VOLUME (IU)
11.3.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.2.4 OTHERS
11.3.1.1.3. CLOBETASOL, BY BRAND
11.3.1.1.3.1 TEMOVATE
11.3.1.1.3.1.1. MARKET VALUE (USD MN)
11.3.1.1.3.1.2. MARKET VOLUME (IU)
11.3.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.3.2 CLOBEX
11.3.1.1.3.2.1. MARKET VALUE (USD MN)
11.3.1.1.3.2.2. MARKET VOLUME (IU)
11.3.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.3.3 OLUX
11.3.1.1.3.3.1. MARKET VALUE (USD MN)
11.3.1.1.3.3.2. MARKET VOLUME (IU)
11.3.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.3.4 OTHERS
11.3.1.2. CALCINEURIN INHIBITORS
11.3.1.2.1. TACROLIMUS, BY BRAND
11.3.1.2.1.1 PROGRAF
11.3.1.2.1.1.1. MARKET VALUE (USD MN)
11.3.1.2.1.1.2. MARKET VOLUME (IU)
11.3.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.2.1.2 ENVARSUS XR
11.3.1.2.1.2.1. MARKET VALUE (USD MN)
11.3.1.2.1.2.2. MARKET VOLUME (IU)
11.3.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.2.1.3 ASTAGRAF XL
11.3.1.2.1.3.1. MARKET VALUE (USD MN)
11.3.1.2.1.3.2. MARKET VOLUME (IU)
11.3.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.2.1.4 OTHERS
11.3.1.2.2. PIMECROLIMUS (ELIDEL)
11.3.1.2.2.1.1. MARKET VALUE (USD MN)
11.3.1.2.2.1.2. MARKET VOLUME (IU)
11.3.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.3. IMMUNOSUPPRESSANT
11.3.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.3.1.3.1.1 SANDMMUNE
11.3.1.3.1.1.1. MARKET VALUE (USD MN)
11.3.1.3.1.1.2. MARKET VOLUME (IU)
11.3.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.1.2 NEORAL
11.3.1.3.1.2.1. MARKET VALUE (USD MN)
11.3.1.3.1.2.2. MARKET VOLUME (IU)
11.3.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.1.3 RESTASIS
11.3.1.3.1.3.1. MARKET VALUE (USD MN)
11.3.1.3.1.3.2. MARKET VOLUME (IU)
11.3.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.1.4 OTHERS
11.3.1.3.2. METHOTREXATE, BY BRAND NAME
11.3.1.3.2.1 TREXALL
11.3.1.3.2.1.1. MARKET VALUE (USD MN)
11.3.1.3.2.1.2. MARKET VOLUME (IU)
11.3.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.2.2 OTREXUP
11.3.1.3.2.2.1. MARKET VALUE (USD MN)
11.3.1.3.2.2.2. MARKET VOLUME (IU)
11.3.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.2.3 RASUVO
11.3.1.3.2.3.1. MARKET VALUE (USD MN)
11.3.1.3.2.3.2. MARKET VOLUME (IU)
11.3.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.2.4 OTHERS
11.3.1.3.3. BIOLOGIC DRUGS
11.3.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.3.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.3.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.3.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.3.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.1.6. OTHERS
11.3.1.3.3.2 INTERLEUKIN
11.3.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.2.4. OTHERS
11.3.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.4. OTHERS
11.3.2 TOPICAL THERAPY
11.3.2.1. VITAMIN D
11.3.2.1.1. CALCIPOTRIENE,BY BRAND
11.3.2.1.1.1 DOVONEX
11.3.2.1.1.1.1. MARKET VALUE (USD MN)
11.3.2.1.1.1.2. MARKET VOLUME (IU)
11.3.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.2.1.1.2 SORILUX
11.3.2.1.1.2.1. MARKET VALUE (USD MN)
11.3.2.1.1.2.2. MARKET VOLUME (IU)
11.3.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.2.1.1.3 OTHERS
11.3.2.1.2. CALCITRIOL (VECTICAL)
11.3.2.1.2.1 MARKET VALUE (USD MN)
11.3.2.1.2.2 MARKET VOLUME (IU)
11.3.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.3.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.3.2.2.1. TAZORAC
11.3.2.2.1.1 MARKET VALUE (USD MN)
11.3.2.2.1.2 MARKET VOLUME (IU)
11.3.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.2. AVAGE
11.3.2.2.2.1 MARKET VALUE (USD MN)
11.3.2.2.2.2 MARKET VOLUME (IU)
11.3.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.3. OTHERS
11.3.2.3. ANTHRALIN
11.3.2.3.1. MARKET VALUE (USD MN)
11.3.2.3.2. MARKET VOLUME (IU)
11.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.2.4. SALICYLIC ACID
11.3.2.4.1. MARKET VALUE (USD MN)
11.3.2.4.2. MARKET VOLUME (IU)
11.3.2.4.3. AVERAGE SELLING PRICE (USD)
11.3.2.5. COAL TAR
11.3.2.5.1. MARKET VALUE (USD MN)
11.3.2.5.2. MARKET VOLUME (IU)
11.3.2.5.3. AVERAGE SELLING PRICE (USD)
11.3.2.6. OTHERS
11.3.3 LIGHT THERAPY
11.3.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.3.3.2. UV B
11.3.3.2.1. BROAD BAND
11.3.3.2.2. NARROW BAND
11.3.3.3. EXCIMER LASER
11.3.4 SYMPTOMATIC MEDICINE
11.3.4.1. ALOE EXTRACT CREAM
11.3.4.1.1. MARKET VALUE (USD MN)
11.3.4.1.2. MARKET VOLUME (IU)
11.3.4.1.3. AVERAGE SELLING PRICE (USD)
11.3.4.2. FISH OIL SUPPLEMENTS
11.3.4.2.1. MARKET VALUE (USD MN)
11.3.4.2.2. MARKET VOLUME (IU)
11.3.4.2.3. AVERAGE SELLING PRICE (USD)
11.3.4.3. OREGON GRAPE
11.3.4.3.1. MARKET VALUE (USD MN)
11.3.4.3.2. MARKET VOLUME (IU)
11.3.4.3.3. AVERAGE SELLING PRICE (USD)
11.4 INVERSE PSORIASIS
11.4.1 MEDICATION
11.4.1.1. CORTICOSTEROIDS
11.4.1.1.1. HYDROCORTISONE, BY BRAND
11.4.1.1.1.1 HYDROCORT
11.4.1.1.1.1.1. MARKET VALUE (USD MN)
11.4.1.1.1.1.2. MARKET VOLUME (IU)
11.4.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.1.2 ALPHOSYL
11.4.1.1.1.2.1. MARKET VALUE (USD MN)
11.4.1.1.1.2.2. MARKET VOLUME (IU)
11.4.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.1.3 AQUACORT
11.4.1.1.1.3.1. MARKET VALUE (USD MN)
11.4.1.1.1.3.2. MARKET VOLUME (IU)
11.4.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.1.4 OTHERS
11.4.1.1.2. TRIAMCINOLONE, BY BRAND
11.4.1.1.2.1 KENALOG IV
11.4.1.1.2.1.1. MARKET VALUE (USD MN)
11.4.1.1.2.1.2. MARKET VOLUME (IU)
11.4.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.2.2 ARISTOSPAN
11.4.1.1.2.2.1. MARKET VALUE (USD MN)
11.4.1.1.2.2.2. MARKET VOLUME (IU)
11.4.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.2.3 TRIVARIS
11.4.1.1.2.3.1. MARKET VALUE (USD MN)
11.4.1.1.2.3.2. MARKET VOLUME (IU)
11.4.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.2.4 OTHERS
11.4.1.1.3. CLOBETASOL, BY BRAND
11.4.1.1.3.1 TEMOVATE
11.4.1.1.3.1.1. MARKET VALUE (USD MN)
11.4.1.1.3.1.2. MARKET VOLUME (IU)
11.4.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.3.2 CLOBEX
11.4.1.1.3.2.1. MARKET VALUE (USD MN)
11.4.1.1.3.2.2. MARKET VOLUME (IU)
11.4.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.3.3 OLUX
11.4.1.1.3.3.1. MARKET VALUE (USD MN)
11.4.1.1.3.3.2. MARKET VOLUME (IU)
11.4.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.3.4 OTHERS
11.4.1.2. CALCINEURIN INHIBITORS
11.4.1.2.1. TACROLIMUS, BY BRAND
11.4.1.2.1.1 PROGRAF
11.4.1.2.1.1.1. MARKET VALUE (USD MN)
11.4.1.2.1.1.2. MARKET VOLUME (IU)
11.4.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.2.1.2 ENVARSUS XR
11.4.1.2.1.2.1. MARKET VALUE (USD MN)
11.4.1.2.1.2.2. MARKET VOLUME (IU)
11.4.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.2.1.3 ASTAGRAF XL
11.4.1.2.1.3.1. MARKET VALUE (USD MN)
11.4.1.2.1.3.2. MARKET VOLUME (IU)
11.4.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.2.1.4 OTHERS
11.4.1.2.2. PIMECROLIMUS (ELIDEL)
11.4.1.2.2.1.1. MARKET VALUE (USD MN)
11.4.1.2.2.1.2. MARKET VOLUME (IU)
11.4.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.3. IMMUNOSUPPRESSANT
11.4.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.4.1.3.1.1 SANDMMUNE
11.4.1.3.1.1.1. MARKET VALUE (USD MN)
11.4.1.3.1.1.2. MARKET VOLUME (IU)
11.4.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.1.2 NEORAL
11.4.1.3.1.2.1. MARKET VALUE (USD MN)
11.4.1.3.1.2.2. MARKET VOLUME (IU)
11.4.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.1.3 RESTASIS
11.4.1.3.1.3.1. MARKET VALUE (USD MN)
11.4.1.3.1.3.2. MARKET VOLUME (IU)
11.4.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.1.4 OTHERS
11.4.1.3.2. METHOTREXATE, BY BRAND NAME
11.4.1.3.2.1 TREXALL
11.4.1.3.2.1.1. MARKET VALUE (USD MN)
11.4.1.3.2.1.2. MARKET VOLUME (IU)
11.4.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.2.2 OTREXUP
11.4.1.3.2.2.1. MARKET VALUE (USD MN)
11.4.1.3.2.2.2. MARKET VOLUME (IU)
11.4.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.2.3 RASUVO
11.4.1.3.2.3.1. MARKET VALUE (USD MN)
11.4.1.3.2.3.2. MARKET VOLUME (IU)
11.4.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.2.4 OTHERS
11.4.1.3.3. BIOLOGIC DRUGS
11.4.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.4.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.4.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.4.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.4.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.1.6. OTHERS
11.4.1.3.3.2 INTERLEUKIN
11.4.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.2.4. OTHERS
11.4.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.4. OTHERS
11.4.2 TOPICAL THERAPY
11.4.2.1. VITAMIN D
11.4.2.1.1. CALCIPOTRIENE,BY BRAND
11.4.2.1.1.1 DOVONEX
11.4.2.1.1.1.1. MARKET VALUE (USD MN)
11.4.2.1.1.1.2. MARKET VOLUME (IU)
11.4.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.2.1.1.2 SORILUX
11.4.2.1.1.2.1. MARKET VALUE (USD MN)
11.4.2.1.1.2.2. MARKET VOLUME (IU)
11.4.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.2.1.1.3 OTHERS
11.4.2.1.2. CALCITRIOL (VECTICAL)
11.4.2.1.2.1 MARKET VALUE (USD MN)
11.4.2.1.2.2 MARKET VOLUME (IU)
11.4.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.4.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.4.2.2.1. TAZORAC
11.4.2.2.1.1 MARKET VALUE (USD MN)
11.4.2.2.1.2 MARKET VOLUME (IU)
11.4.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.4.2.2.2. AVAGE
11.4.2.2.2.1 MARKET VALUE (USD MN)
11.4.2.2.2.2 MARKET VOLUME (IU)
11.4.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.4.2.2.3. OTHERS
11.4.2.3. ANTHRALIN
11.4.2.3.1. MARKET VALUE (USD MN)
11.4.2.3.2. MARKET VOLUME (IU)
11.4.2.3.3. AVERAGE SELLING PRICE (USD)
11.4.2.4. SALICYLIC ACID
11.4.2.4.1. MARKET VALUE (USD MN)
11.4.2.4.2. MARKET VOLUME (IU)
11.4.2.4.3. AVERAGE SELLING PRICE (USD)
11.4.2.5. COAL TAR
11.4.2.5.1. MARKET VALUE (USD MN)
11.4.2.5.2. MARKET VOLUME (IU)
11.4.2.5.3. AVERAGE SELLING PRICE (USD)
11.4.2.6. OTHERS
11.4.3 LIGHT THERAPY
11.4.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.4.3.2. UV B
11.4.3.2.1. BROAD BAND
11.4.3.2.2. NARROW BAND
11.4.3.3. EXCIMER LASER
11.4.4 SYMPTOMATIC MEDICINE
11.4.4.1. ALOE EXTRACT CREAM
11.4.4.1.1. MARKET VALUE (USD MN)
11.4.4.1.2. MARKET VOLUME (IU)
11.4.4.1.3. AVERAGE SELLING PRICE (USD)
11.4.4.2. FISH OIL SUPPLEMENTS
11.4.4.2.1. MARKET VALUE (USD MN)
11.4.4.2.2. MARKET VOLUME (IU)
11.4.4.2.3. AVERAGE SELLING PRICE (USD)
11.4.4.3. OREGON GRAPE
11.4.4.3.1. MARKET VALUE (USD MN)
11.4.4.3.2. MARKET VOLUME (IU)
11.4.4.3.3. AVERAGE SELLING PRICE (USD)
11.5 PUSTULAR PSORIASIS
11.5.1 MEDICATION
11.5.1.1. CORTICOSTEROIDS
11.5.1.1.1. HYDROCORTISONE, BY BRAND
11.5.1.1.1.1 HYDROCORT
11.5.1.1.1.1.1. MARKET VALUE (USD MN)
11.5.1.1.1.1.2. MARKET VOLUME (IU)
11.5.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.1.2 ALPHOSYL
11.5.1.1.1.2.1. MARKET VALUE (USD MN)
11.5.1.1.1.2.2. MARKET VOLUME (IU)
11.5.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.1.3 AQUACORT
11.5.1.1.1.3.1. MARKET VALUE (USD MN)
11.5.1.1.1.3.2. MARKET VOLUME (IU)
11.5.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.1.4 OTHERS
11.5.1.1.2. TRIAMCINOLONE, BY BRAND
11.5.1.1.2.1 KENALOG IV
11.5.1.1.2.1.1. MARKET VALUE (USD MN)
11.5.1.1.2.1.2. MARKET VOLUME (IU)
11.5.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.2.2 ARISTOSPAN
11.5.1.1.2.2.1. MARKET VALUE (USD MN)
11.5.1.1.2.2.2. MARKET VOLUME (IU)
11.5.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.2.3 TRIVARIS
11.5.1.1.2.3.1. MARKET VALUE (USD MN)
11.5.1.1.2.3.2. MARKET VOLUME (IU)
11.5.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.2.4 OTHERS
11.5.1.1.3. CLOBETASOL, BY BRAND
11.5.1.1.3.1 TEMOVATE
11.5.1.1.3.1.1. MARKET VALUE (USD MN)
11.5.1.1.3.1.2. MARKET VOLUME (IU)
11.5.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.3.2 CLOBEX
11.5.1.1.3.2.1. MARKET VALUE (USD MN)
11.5.1.1.3.2.2. MARKET VOLUME (IU)
11.5.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.3.3 OLUX
11.5.1.1.3.3.1. MARKET VALUE (USD MN)
11.5.1.1.3.3.2. MARKET VOLUME (IU)
11.5.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.3.4 OTHERS
11.5.1.2. CALCINEURIN INHIBITORS
11.5.1.2.1. TACROLIMUS, BY BRAND
11.5.1.2.1.1 PROGRAF
11.5.1.2.1.1.1. MARKET VALUE (USD MN)
11.5.1.2.1.1.2. MARKET VOLUME (IU)
11.5.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.2.1.2 ENVARSUS XR
11.5.1.2.1.2.1. MARKET VALUE (USD MN)
11.5.1.2.1.2.2. MARKET VOLUME (IU)
11.5.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.2.1.3 ASTAGRAF XL
11.5.1.2.1.3.1. MARKET VALUE (USD MN)
11.5.1.2.1.3.2. MARKET VOLUME (IU)
11.5.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.2.1.4 OTHERS
11.5.1.2.2. PIMECROLIMUS (ELIDEL)
11.5.1.2.2.1.1. MARKET VALUE (USD MN)
11.5.1.2.2.1.2. MARKET VOLUME (IU)
11.5.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.3. IMMUNOSUPPRESSANT
11.5.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.5.1.3.1.1 SANDMMUNE
11.5.1.3.1.1.1. MARKET VALUE (USD MN)
11.5.1.3.1.1.2. MARKET VOLUME (IU)
11.5.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.1.2 NEORAL
11.5.1.3.1.2.1. MARKET VALUE (USD MN)
11.5.1.3.1.2.2. MARKET VOLUME (IU)
11.5.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.1.3 RESTASIS
11.5.1.3.1.3.1. MARKET VALUE (USD MN)
11.5.1.3.1.3.2. MARKET VOLUME (IU)
11.5.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.1.4 OTHERS
11.5.1.3.2. METHOTREXATE, BY BRAND NAME
11.5.1.3.2.1 TREXALL
11.5.1.3.2.1.1. MARKET VALUE (USD MN)
11.5.1.3.2.1.2. MARKET VOLUME (IU)
11.5.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.2.2 OTREXUP
11.5.1.3.2.2.1. MARKET VALUE (USD MN)
11.5.1.3.2.2.2. MARKET VOLUME (IU)
11.5.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.2.3 RASUVO
11.5.1.3.2.3.1. MARKET VALUE (USD MN)
11.5.1.3.2.3.2. MARKET VOLUME (IU)
11.5.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.2.4 OTHERS
11.5.1.3.3. BIOLOGIC DRUGS
11.5.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.5.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.5.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.5.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.5.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.1.6. OTHERS
11.5.1.3.3.2 INTERLEUKIN
11.5.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.2.4. OTHERS
11.5.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.4. OTHERS
11.5.2 TOPICAL THERAPY
11.5.2.1. VITAMIN D
11.5.2.1.1. CALCIPOTRIENE,BY BRAND
11.5.2.1.1.1 DOVONEX
11.5.2.1.1.1.1. MARKET VALUE (USD MN)
11.5.2.1.1.1.2. MARKET VOLUME (IU)
11.5.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.2.1.1.2 SORILUX
11.5.2.1.1.2.1. MARKET VALUE (USD MN)
11.5.2.1.1.2.2. MARKET VOLUME (IU)
11.5.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.2.1.1.3 OTHERS
11.5.2.1.2. CALCITRIOL (VECTICAL)
11.5.2.1.2.1 MARKET VALUE (USD MN)
11.5.2.1.2.2 MARKET VOLUME (IU)
11.5.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.5.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.5.2.2.1. TAZORAC
11.5.2.2.1.1 MARKET VALUE (USD MN)
11.5.2.2.1.2 MARKET VOLUME (IU)
11.5.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.5.2.2.2. AVAGE
11.5.2.2.2.1 MARKET VALUE (USD MN)
11.5.2.2.2.2 MARKET VOLUME (IU)
11.5.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.5.2.2.3. OTHERS
11.5.2.3. ANTHRALIN
11.5.2.3.1. MARKET VALUE (USD MN)
11.5.2.3.2. MARKET VOLUME (IU)
11.5.2.3.3. AVERAGE SELLING PRICE (USD)
11.5.2.4. SALICYLIC ACID
11.5.2.4.1. MARKET VALUE (USD MN)
11.5.2.4.2. MARKET VOLUME (IU)
11.5.2.4.3. AVERAGE SELLING PRICE (USD)
11.5.2.5. COAL TAR
11.5.2.5.1. MARKET VALUE (USD MN)
11.5.2.5.2. MARKET VOLUME (IU)
11.5.2.5.3. AVERAGE SELLING PRICE (USD)
11.5.2.6. OTHERS
11.5.3 LIGHT THERAPY
11.5.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.5.3.2. UV B
11.5.3.2.1. BROAD BAND
11.5.3.2.2. NARROW BAND
11.5.3.3. EXCIMER LASER
11.5.4 SYMPTOMATIC MEDICINE
11.5.4.1. ALOE EXTRACT CREAM
11.5.4.1.1. MARKET VALUE (USD MN)
11.5.4.1.2. MARKET VOLUME (IU)
11.5.4.1.3. AVERAGE SELLING PRICE (USD)
11.5.4.2. FISH OIL SUPPLEMENTS
11.5.4.2.1. MARKET VALUE (USD MN)
11.5.4.2.2. MARKET VOLUME (IU)
11.5.4.2.3. AVERAGE SELLING PRICE (USD)
11.5.4.3. OREGON GRAPE
11.5.4.3.1. MARKET VALUE (USD MN)
11.5.4.3.2. MARKET VOLUME (IU)
11.5.4.3.3. AVERAGE SELLING PRICE (USD)
11.6 ERYTHRODERMIC PSORIASIS
11.6.1 MEDICATION
11.6.1.1. CORTICOSTEROIDS
11.6.1.1.1. HYDROCORTISONE, BY BRAND
11.6.1.1.1.1 HYDROCORT
11.6.1.1.1.1.1. MARKET VALUE (USD MN)
11.6.1.1.1.1.2. MARKET VOLUME (IU)
11.6.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.1.2 ALPHOSYL
11.6.1.1.1.2.1. MARKET VALUE (USD MN)
11.6.1.1.1.2.2. MARKET VOLUME (IU)
11.6.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.1.3 AQUACORT
11.6.1.1.1.3.1. MARKET VALUE (USD MN)
11.6.1.1.1.3.2. MARKET VOLUME (IU)
11.6.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.1.4 OTHERS
11.6.1.1.2. TRIAMCINOLONE, BY BRAND
11.6.1.1.2.1 KENALOG IV
11.6.1.1.2.1.1. MARKET VALUE (USD MN)
11.6.1.1.2.1.2. MARKET VOLUME (IU)
11.6.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.2.2 ARISTOSPAN
11.6.1.1.2.2.1. MARKET VALUE (USD MN)
11.6.1.1.2.2.2. MARKET VOLUME (IU)
11.6.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.2.3 TRIVARIS
11.6.1.1.2.3.1. MARKET VALUE (USD MN)
11.6.1.1.2.3.2. MARKET VOLUME (IU)
11.6.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.2.4 OTHERS
11.6.1.1.3. CLOBETASOL, BY BRAND
11.6.1.1.3.1 TEMOVATE
11.6.1.1.3.1.1. MARKET VALUE (USD MN)
11.6.1.1.3.1.2. MARKET VOLUME (IU)
11.6.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.3.2 CLOBEX
11.6.1.1.3.2.1. MARKET VALUE (USD MN)
11.6.1.1.3.2.2. MARKET VOLUME (IU)
11.6.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.3.3 OLUX
11.6.1.1.3.3.1. MARKET VALUE (USD MN)
11.6.1.1.3.3.2. MARKET VOLUME (IU)
11.6.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.3.4 OTHERS
11.6.1.2. CALCINEURIN INHIBITORS
11.6.1.2.1. TACROLIMUS, BY BRAND
11.6.1.2.1.1 PROGRAF
11.6.1.2.1.1.1. MARKET VALUE (USD MN)
11.6.1.2.1.1.2. MARKET VOLUME (IU)
11.6.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.2.1.2 ENVARSUS XR
11.6.1.2.1.2.1. MARKET VALUE (USD MN)
11.6.1.2.1.2.2. MARKET VOLUME (IU)
11.6.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.2.1.3 ASTAGRAF XL
11.6.1.2.1.3.1. MARKET VALUE (USD MN)
11.6.1.2.1.3.2. MARKET VOLUME (IU)
11.6.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.2.1.4 OTHERS
11.6.1.2.2. PIMECROLIMUS (ELIDEL)
11.6.1.2.2.1.1. MARKET VALUE (USD MN)
11.6.1.2.2.1.2. MARKET VOLUME (IU)
11.6.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.3. IMMUNOSUPPRESSANT
11.6.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.6.1.3.1.1 SANDMMUNE
11.6.1.3.1.1.1. MARKET VALUE (USD MN)
11.6.1.3.1.1.2. MARKET VOLUME (IU)
11.6.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.1.2 NEORAL
11.6.1.3.1.2.1. MARKET VALUE (USD MN)
11.6.1.3.1.2.2. MARKET VOLUME (IU)
11.6.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.1.3 RESTASIS
11.6.1.3.1.3.1. MARKET VALUE (USD MN)
11.6.1.3.1.3.2. MARKET VOLUME (IU)
11.6.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.1.4 OTHERS
11.6.1.3.2. METHOTREXATE, BY BRAND NAME
11.6.1.3.2.1 TREXALL
11.6.1.3.2.1.1. MARKET VALUE (USD MN)
11.6.1.3.2.1.2. MARKET VOLUME (IU)
11.6.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.2.2 OTREXUP
11.6.1.3.2.2.1. MARKET VALUE (USD MN)
11.6.1.3.2.2.2. MARKET VOLUME (IU)
11.6.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.2.3 RASUVO
11.6.1.3.2.3.1. MARKET VALUE (USD MN)
11.6.1.3.2.3.2. MARKET VOLUME (IU)
11.6.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.2.4 OTHERS
11.6.1.3.3. BIOLOGIC DRUGS
11.6.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.6.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.6.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.6.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.6.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.1.6. OTHERS
11.6.1.3.3.2 INTERLEUKIN
11.6.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.2.4. OTHERS
11.6.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.4. OTHERS
11.6.2 TOPICAL THERAPY
11.6.2.1. VITAMIN D
11.6.2.1.1. CALCIPOTRIENE,BY BRAND
11.6.2.1.1.1 DOVONEX
11.6.2.1.1.1.1. MARKET VALUE (USD MN)
11.6.2.1.1.1.2. MARKET VOLUME (IU)
11.6.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.2.1.1.2 SORILUX
11.6.2.1.1.2.1. MARKET VALUE (USD MN)
11.6.2.1.1.2.2. MARKET VOLUME (IU)
11.6.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.2.1.1.3 OTHERS
11.6.2.1.2. CALCITRIOL (VECTICAL)
11.6.2.1.2.1 MARKET VALUE (USD MN)
11.6.2.1.2.2 MARKET VOLUME (IU)
11.6.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.6.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.6.2.2.1. TAZORAC
11.6.2.2.1.1 MARKET VALUE (USD MN)
11.6.2.2.1.2 MARKET VOLUME (IU)
11.6.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.2. AVAGE
11.6.2.2.2.1 MARKET VALUE (USD MN)
11.6.2.2.2.2 MARKET VOLUME (IU)
11.6.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.3. OTHERS
11.6.2.3. ANTHRALIN
11.6.2.3.1. MARKET VALUE (USD MN)
11.6.2.3.2. MARKET VOLUME (IU)
11.6.2.3.3. AVERAGE SELLING PRICE (USD)
11.6.2.4. SALICYLIC ACID
11.6.2.4.1. MARKET VALUE (USD MN)
11.6.2.4.2. MARKET VOLUME (IU)
11.6.2.4.3. AVERAGE SELLING PRICE (USD)
11.6.2.5. COAL TAR
11.6.2.5.1. MARKET VALUE (USD MN)
11.6.2.5.2. MARKET VOLUME (IU)
11.6.2.5.3. AVERAGE SELLING PRICE (USD)
11.6.2.6. OTHERS
11.6.3 LIGHT THERAPY
11.6.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.6.3.2. UV B
11.6.3.2.1. BROAD BAND
11.6.3.2.2. NARROW BAND
11.6.3.3. EXCIMER LASER
11.6.4 SYMPTOMATIC MEDICINE
11.6.4.1. ALOE EXTRACT CREAM
11.6.4.1.1. MARKET VALUE (USD MN)
11.6.4.1.2. MARKET VOLUME (IU)
11.6.4.1.3. AVERAGE SELLING PRICE (USD)
11.6.4.2. FISH OIL SUPPLEMENTS
11.6.4.2.1. MARKET VALUE (USD MN)
11.6.4.2.2. MARKET VOLUME (IU)
11.6.4.2.3. AVERAGE SELLING PRICE (USD)
11.6.4.3. OREGON GRAPE
11.6.4.3.1. MARKET VALUE (USD MN)
11.6.4.3.2. MARKET VOLUME (IU)
11.6.4.3.3. AVERAGE SELLING PRICE (USD)
12 GLOBAL PSORIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLETS
12.2.2 PILLS
12.2.3 OTHERS
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 SUBCUTANEOUS
12.3.3 OTHERS
12.4 TOPICAL
12.4.1 GEL
12.4.2 CREAM
12.4.3 FOAM
12.4.4 OINTMENTS
12.4.5 SPRAY
12.4.6 SHAMPOO
12.4.7 LOTION
12.4.8 OTHERS
13 GLOBAL PSORIASIS TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 THERAPY CENTERS
13.6 OTHERS
14 GLOBAL PSORIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 HOSPITAL PHARMACY
14.4 RETAIL PHARMACY
14.5 ONLINE PHARMACY
14.6 OTHERS
15 GLOBAL PSORIASIS TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL PSORIASIS TREATMENT MARKET, BY GEOGRAPHY
16.1 GLOBAL PSORIASIS TREATMENT MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.1.1. U.S. PSORIASIS TREATMENT MARKET, BY TYPE
16.2.1.2. U.S. PSORIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
16.2.1.3. U.S. PSORIASIS TREATMENT MARKET, BY END USER
16.2.1.4. U.S. PSORIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.3 CANADA
16.3.1 MEXICO
16.3.2 DOMINICAN REPUBLIC
16.3.3 JAMAICA
16.3.4 PANAMA
16.4 EUROPE
16.4.1 GERMANY
16.4.2 FRANCE
16.4.3 U.K.
16.4.4 HUNGARY
16.4.5 LITHUANIA
16.4.6 AUSTRIA
16.4.7 IRELAND
16.4.8 NORWAY
16.4.9 POLAND
16.4.10 ITALY
16.4.11 SPAIN
16.4.12 RUSSIA
16.4.13 TURKEY
16.4.14 NETHERLANDS
16.4.15 SWITZERLAND
16.4.16 REST OF EUROPE
16.5 ASIA-PACIFIC
16.5.1 JAPAN
16.5.2 CHINA
16.5.3 TAIWAN
16.5.4 SOUTH KOREA
16.5.5 INDIA
16.5.6 AUSTRALIA
16.5.7 SINGAPORE
16.5.8 THAILAND
16.5.9 MALAYSIA
16.5.10 INDONESIA
16.5.11 PHILIPPINES
16.5.12 VIETNAM
16.5.13 REST OF ASIA-PACIFIC
16.6 SOUTH AMERICA
16.6.1 BRAZIL
16.6.2 ECUADOR
16.6.3 CHILE
16.6.4 COLOMBIA
16.6.5 VENEZUELA
16.6.6 ARGENTINA
16.6.7 PERU
16.6.8 CURAÇAO
16.6.9 PARAGUAY
16.6.10 URUGUAY
16.6.11 TRINIDAD AND TOBAGO
16.6.12 REST OF SOUTH AMERICA
16.7 MIDDLE EAST AND AFRICA
16.7.1 SOUTH AFRICA
16.7.2 SAUDI ARABIA
16.7.3 UAE
16.7.4 EGYPT
16.7.5 KUWAIT
16.7.6 ISRAEL
16.7.7 BOLIVIA
16.7.8 REST OF MIDDLE EAST AND AFRICA
16.7.9 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL PSORIASIS TREATMENT MARKET, SWOT AND DBMR ANALYSIS
18 GLOBAL PSORIASIS TREATMENT MARKET, COMPANY PROFILE
18.1 PERRIGO COMPANY PLC
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 SANOFI
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 GLAXOSMITHKLINE
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 MERCK & CO, INC
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 F-HOFFMANN LA ROCHE
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 PFIZER
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 JOHNSON & JOHNSON
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 COSETTE PHARMACEUTICALS, INC.
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 LUPIN
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.9.6 MYLAN N.V.
18.9.7 COMPANY OVERVIEW
18.9.8 REVENUE ANALYSIS
18.9.9 GEOGRAPHIC PRESENCE
18.9.10 PRODUCT PORTFOLIO
18.9.11 RECENT DEVELOPMENTS
18.1 WOCKHARDT
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 TOLMAR PHARMACEUTICALS, INC.
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 AKORN, INCORPORATED
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 TELIGENT
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 GLENMARK PHARMACEUTICAL INC.
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 XIROMED
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 AMNEAL PHARMACEUTICALS LLC
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 ENCUBE ETHICALS
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 INGENUS PHARMACEUTICALS, LLC
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 ALEOR DERMACEUTICALS LIMITED
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 SANDOZ AG
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 ENCORE DERMATOLOGY, INC.,
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 ZYDUS PHARMACEUTICALS, INC.
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 TEVA PHARMACEUTICALS USA, INC.
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 STIEFEL LABORATORIES, INC.
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 SIGMAPHARM LABORATORIES, LLC.
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPMENTS
18.26 THE DAAVLIN COMPANY
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
